IOLCP Q2 & H1 FY27: Revenue up 40% to ₹795 Cr, PAT jumps 117% to ₹65 Cr
IOLCP reported a 40% YoY revenue increase to ₹795 Cr in Q2 FY27, with PAT soaring 117% to ₹65 Cr. H1 FY27 revenue grew 39% to ₹1,551 Cr, and PAT more than doubled to ₹130 Cr. The company is investing ₹500 Cr in capacity expansion and new facilities, targeting FY27/FY28 commencement. Full-year revenue growth is projected above 25%.
The significant year-on-year growth in revenue and profit, coupled with substantial investments in capacity expansion and new business initiatives like CDMO and specialty chemicals, are material developments that are expected to have a significant positive impact on the company's future financial performance and market position.
The company reported strong financial growth in revenue, EBITDA, and PAT for Q2 and H1 FY27, exceeding expectations and demonstrating robust performance across its business segments. The strategic investments in capacity expansion and new facilities indicate a positive outlook for future growth.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) announced its financial results for the second quarter (Q2) and first half (H1) of the fiscal year 2027 (FY27), reporting significant year-on-year growth across key financial metrics.
In Q2 FY27, the company's revenue from operations reached ₹795 crore, marking a substantial 40% increase year-on-year and a high sequential growth. For H1 FY27, revenue from operations grew by approximately 39% year-on-year to ₹1,551 crore. This robust performance was attributed to healthy demand in both the pharmaceuticals and chemicals businesses, coupled with an improved product mix.
EBITDA for Q2 FY27 stood at approximately ₹115 crore, an 80% increase compared to ₹64 crore in the corresponding quarter of FY26. The EBITDA margin improved to 14.4% from 11.2% year-on-year. For H1 FY27, EBITDA rose by about 70% year-on-year to ₹227 crore, with an EBITDA margin of 14.5% compared to 11.8% in H1 FY26.
Profit After Tax (PAT) saw a significant surge, with Q2 FY27 PAT at approximately ₹65 crore, a 117% jump from ₹30 crore in Q2 FY26. For H1 FY27, PAT more than doubled year-on-year to approximately ₹130 crore from ₹64 crore.
The company highlighted strong performance in its pharmaceuticals business, with the non-ibuprofen portfolio growing by approximately 70% year-on-year in Q2 FY27, contributing 45% of pharmaceutical revenue. The chemicals business also showed marked improvement, with its contribution to overall EBIT increasing to around 7% from 1% in the previous year.
Strategic initiatives include three manufacturing projects with a combined investment of approximately ₹500 crore, funded through internal accruals. These projects involve expanding ibuprofen manufacturing capacity to 18,000 MTPA, establishing a formulation CDMO facility with a capacity of 1,500 million tablets, and setting up a dedicated specialty chemicals facility. The CDMO and specialty chemical projects are expected to commence operations in FY27, while the ibuprofen expansion is targeted for commissioning in FY28.
Regulatory milestones achieved include receiving a certificate of suitability from EDQM for Fenofibrate - Process II, bringing the total CEP approvals to 22, and obtaining GMP certification for the formulation CDMO facility. EU-REACH registrations were secured for triacetin.
The company projects a full-year revenue growth of over 25% for FY27, with an expected EBITDA margin of 14% to 15%. The management anticipates that the sustainable EBITDA margin for the company as a whole could range between 15% to 17%.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.